provider image
Welcome! You’re in GoodRx for healthcare professionals. Now, you’ll enjoy a streamlined experience created specifically for healthcare professionals.
Skip to main content

Lartruvo

olaratumab
Used for Soft Tissue Sarcoma
Used for Soft Tissue Sarcoma

Lartruvo (olaratumab) is an injectable medication that's given together with doxorubicin (Adriamycin) for the treatment of soft tissue sarcoma (STS) in adults who can't get surgery or radiotherapy. This medication was taken off the market and is no longer available in the U.S.

Last reviewed on July 31, 2022
basics-icon

What is Lartruvo (olaratumab)?

What is Lartruvo (olaratumab) used for?

  • Soft tissue sarcoma (STS)

How Lartruvo (olaratumab) works

Are you looking for information on Lynparza (olaparib) instead?

Drug Facts

Common BrandsLartruvo (brand no longer available)
Drug ClassAnticancer
Controlled Substance ClassificationNot a controlled medication
Generic StatusNo lower-cost generic available
AvailabilityDiscontinued
faqs

Frequently asked questions about Lartruvo (olaratumab)

What is Lartruvo (olaratumab)?
Lartruvo (olaratumab) is an anticancer medication used to treat soft tissue sarcoma (STS) for people who can't get surgery or radiotherapy. This medication is given as an infusion into the vein and in combination with doxorubicin (Adriamycin) treatment. Lartruvo (olaratumab) works by attaching to a protein on the surface of cells that's responsible for growth and movement. Since this protein is also found on cancer cells (including those of STS), blocking the protein can help slow or stop the growth of the cancer. Lartruvo (olaratumab) was approved by the FDA in 2016 under their Accelerated Approval program based on early studies showing potential benefits of the medication to people with this rare cancer.
Is Lartruvo (olaratumab) still available?
No, Lartruvo (olaratumab) has been withdrawn from the market and is no longer available.
Why was Lartruvo (olaratumab) discontinued?
Lartruvo (olaratumab) was discontinued by the manufacturer (Eli Lilly and Co.), because there wasn't enough clinical evidence that the medication could improve survival for people with STS. Because of this, the FDA decided to withdraw Lartruvo (olaratumab) from the market. Speak with your provider about other treatment options for your particular STS.
GoodRxEducationalIcon

How to save using GoodRx

Compare Prices
1. Compare PricesSpecify your dosage and quantity to find out exactly how much you can save.
Select your free coupon
2. Select your free couponYou can use the displayed coupon, or compare prices at other pharmacies near you.
Show coupon to your pharmacist
3. Show coupon to your pharmacistPresent your printed or electronic coupon when you pick up your prescription.
Get free couponLearn more

Get savings updates for Lartruvo (olaratumab)

Receive price alerts, news, and other messages from GoodRx about Lartruvo (olaratumab) and other healthcare topics and relevant savings offers.

By signing up, I agree to GoodRx's Terms and Privacy Policy, and to receive marketing messages from GoodRx.

Browse medications

View All

Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.